Regeneron will present seven oncology abstracts at ESMO 2025, led by new Phase 3 C-POST safety and pharmacokinetic data supporting an every-6-week dosing option for Libtayo (cemiplimab) as adjuvant therapy in cutaneous squamous cell carcinoma with high risk of recurrence after surgery and radiation. The regimen, which began with 350 mg every three weeks for 12 weeks and then shifted most patients to every six weeks up to a total of 48 weeks, showed comparable efficacy, pharmacokinetics, and immunogenicity across dosing intervals with a safety profile consistent with known cemiplimab monotherapy experience. These findings follow the FDA’s recent approval of Libtayo as the first immunotherapy in this adjuvant CSCC setting.
The strategic signal is clear: dosing flexibility is now a frontline competitive lever in a PD-1 class defined by parity on mechanism but divergence on convenience and care delivery economics. Every-6-week administration in the adjuvant setting is not simply a scheduling tweak; it is a commercialization tool that can reduce infusion chair time, smooth clinic throughput, and lower indirect costs for patients and providers without sacrificing clinical performance. The immediate question for brand and market access teams is whether this patient-centric cadence accelerates adoption among dermatologic oncologists, surgeons, and radiation oncologists who are newly navigating adjuvant immunotherapy in CSCC, and whether payers will view reduced recurrence risk and fewer visits as sufficient justification for broad coverage at scale.
For patients—often older, comorbid, and traveling long distances for care—fewer infusions over a one-year course could meaningfully improve adherence and quality of life. For health systems managing capacity constraints, 6-week dosing can expand access without adding infrastructure. Payers will scrutinize absolute and relative risk reductions in recurrence and resource utilization offsets from avoided salvage surgery, complex radiation, and hospitalization. If the dosing flexibility translates into real-world adherence gains, the total cost of care argument strengthens, particularly for Medicare populations where CSCC burden is substantial.
Beyond Libtayo’s dosing update, Regeneron’s ESMO slate underscores a broader strategy to solidify cemiplimab as the backbone of an extensible immuno-oncology platform. A randomized Phase 2 study of ubamatamab in platinum-resistant ovarian cancer, with and without cemiplimab, tests the company’s combination thesis in a population with limited options. Data on mitigating infusion-related reactions for REGN7075, an EGFRxCD28 bispecific, points to the operational know-how required to make costimulatory approaches clinically viable—a necessary step if the CD28 axis is to deliver durable benefit safely. Real-world evidence in immunocompromised or immunosuppressed CSCC patients at 18 months addresses a critical gap, as these populations are routinely underrepresented in trials yet common in CSCC practice; Medical Affairs teams will see immediate utility for guideline discussions and payer evidence packages. An analysis linking patient-reported outcomes to overall survival in first-line NSCLC, alongside machine learning work to predict real-world survival in melanoma, signals a push to integrate outcomes that resonate in value-based negotiations and to build analytic assets that can support external controls and risk-adjusted contracting.
The competitive context is tightening. As PD-1s converge on indications and outcomes, differentiation will hinge on dosing convenience, adjuvant expansion, combination readiness, and the credibility of RWE to unlock access in excluded populations. The near-term markers to watch are European regulatory decisions on adjuvant CSCC and six-week dosing alignment, hazard ratios, and subgroup consistency from C-POST that will shape treatment guidelines, and whether costimulatory bispecifics can show clinically meaningful efficacy with manageable premedication and infusion protocols. The next wave of I-O advantage may be won as much in delivery design and evidence integration as in the receptor the antibody targets.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
